UNCERTAINTIES AND EVOLUTION IN THE TREATMENT OF COVID-19: A PROSPECT

Abstract

The world is facing a pandemic caused by the disease COVID-19, which is a variation of the Coronavirus family that causes respiratory infections. The proposed work brings a study about the uncertainties and evolutions in the treatment against this disease, analyzing the drugs in the clinical trials phase directed to drugs with satisfactory and unsatisfactory degree of efficacy. The theoretical framework is linked to scientific articles in the field of medicine, pharmaceutical laboratories and scientific websites. The search for scientific articles was based on the Academic Google portal and the databases of Scientific Electronic Library Online (SCIELO), Medical Literature Analysis and Retrieval System Online (MEDLINE), Science Direct, among others. In the approach of this study, epidemiological data and laboratory diagnoses of those infected are evidenced, along with the mapping of the drugs Remdesivir, Dexamethasone, Hydroxychloroquine, Lopinavir/Ritonavir (L/R), Umifenovir, Tocilizumab and Molnupiravir. used during the healing process and addressing the uncertainties that permeate this disease. In addition to technological and scientific advances in diagnosis, means of rehabilitation after contamination with SARS-Cov-2, the development of new vaccines approved for the prevention of the disease, such as Oxford, Moderna, Pfizer, BioNTech and CoronaVac (Butantan), is evidenced. We emphasize that not one of the drugs observed played a complete individual role, but early treatment and in patients at an advanced stage saved lives when compared to patients without the use of drugs. Therefore, mass immunization is being the best alternative to prevent deaths and allows for greater safety worldwide.